Erica Slaughter, MS

Although the indication of pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage psychosis symptoms.

Over the past several years, scientific teams have developed investigational methods for delivering a gene to correct a mutation in the DMD gene which causes DMD by creating dysfunction in a patient’s dystrophin production.

Although telestroke programs show more success in bringing stroke care to patients, lingering challenges have prevented widespread implementation.

Several agents are currently in development geared at the relief of off-time for patients with Parkinson.